US FDA panel to discuss Alzheimer's imaging agents
This article was originally published in Scrip
Executive Summary
The US FDA's peripheral and central nervous system drugs advisory panel will meet on October 23rd to discuss the clinical development of radionuclide imaging products for the detection of amyloid. The imaging agents would be used to help diagnose Alzheimer's disease.